Posted inClinical Updates Gastroenterology
Targeting Myofibroblast-Derived Transglutaminase 2: A Novel Therapeutic Avenue for Intestinal Fibrosis in Stricturing Crohn’s Disease
This study reveals that elevated transglutaminase 2 activity from intestinal myofibroblasts drives fibrosis independent of inflammation in stricturing Crohn’s disease and that inhibiting TG2 can reduce fibrotic ECM accumulation, suggesting a promising antifibrotic therapy.